Aktis Oncology, Inc. (AKTS) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-16

Key Insights

This Form 4 filing shows that Glenn Gormley, a director of Aktis Oncology, Inc. (AKTS), was granted a stock option to purchase 37,866 shares of the company's common stock at an exercise price of $18.09 per share.
The option has a 10-year term and vests over a 3-year period, with 1/3 of the shares vesting on April 15, 2027, and the remaining 2/3 vesting in equal annual installments thereafter.
This insider purchase suggests that Gormley is confident in the company's future prospects and aligns his interests with those of shareholders.

Want the newest filings?

This analysis covers the filing from 2026-04-16. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-01-14

Insider Ansbert Gadicke, a director and 10% owner, significantly increased his beneficial ownership of Aktis Oncology through a series of stock acquisitions and conversions.
The reported transactions include the conversion of redeemable convertible preferred stock into common stock, as well as direct purchases of common stock.
The increase in Gadicke's ownership position, both directly and through affiliated investment funds, suggests he has a strong conviction in the company's long-term prospects.

Filed: 2026-01-14

The reporting persons, which include various MPM Capital entities, have converted a significant amount of preferred stock into common stock of Aktis Oncology, Inc. This suggests the investors are bullish on the company's prospects.
The reporting persons have also purchased an additional 1,112,777 shares of common stock at $18 per share, further increasing their ownership stake in the company.
Insider buying activity is often viewed as a positive signal by investors, as it indicates the reporting persons have confidence in the company's future performance.

Filed: 2026-01-14

Insider Todd Foley, who is a 10% owner of Aktis Oncology, Inc. (AKTS), has significantly increased his stake in the company through a series of transactions involving the conversion of preferred stock and open market purchases.
The transactions indicate Foley's strong confidence in the company's long-term prospects, as he has acquired over 4.2 million shares, representing a substantial ownership position.
The timing of these transactions, just prior to the company's initial public offering, suggests Foley believes the stock is undervalued and has the potential for significant upside as the company goes public.

Filed: 2026-01-12

The reporting person, Lloyd Mitchell Segal, has converted 50,000 shares of Series A Redeemable Convertible Preferred Stock and 24,687 shares of Series B Redeemable Convertible Preferred Stock into 19,631 shares of common stock of Aktis Oncology, Inc.
The reporting person owns the converted shares indirectly through his ownership of Arvala, Inc., indicating a concentration of insider ownership.
The conversion of preferred shares to common shares on a 3.8044-for-1 basis suggests a favorable valuation for the reporting person during the company's initial public offering.

Filed: 2026-01-12

The reporting person, Helen Susan Kim, is a director and 10% owner of Aktis Oncology, Inc. (AKTS), indicating significant influence and investment in the company.
Kim has converted Series A and Series B Redeemable Convertible Preferred Stock into common stock, increasing her beneficial ownership to over 5.6 million shares.
The filing suggests insider buying, with Kim purchasing an additional 812,455 shares at $18 per share, further demonstrating confidence in the company's prospects.

Filed: 2026-01-12

Vida Ventures II, LLC and Vida Ventures II-A, LLC, which collectively own over 10% of Aktis Oncology, Inc. (AKTS), have converted their preferred stock holdings into common stock on a 3.8044-for-1 basis.
The reporting persons have also purchased an additional 835,000 shares of AKTS common stock at $18 per share, indicating their continued confidence in the company's prospects.
The conversion of preferred stock and additional purchases suggest that the reporting persons believe in the long-term growth potential of AKTS and are willing to increase their stake in the company.

Filed: 2026-01-12

EcoR1 Capital, LLC, a director and 10% owner of Aktis Oncology, Inc. (AKTS), has acquired a significant amount of common stock and convertible preferred shares through various transactions on January 12, 2026.
The reporting persons, EcoR1 Capital, LLC and Oleg Nodelman, are filing the Form 4 jointly but not as a group, and each disclaims beneficial ownership except for their respective pecuniary interests.
The conversion of Series A and Series B Redeemable Convertible Preferred Stock into common stock and Class A common stock on a 3.8044-for-1 basis suggests a potential capital restructuring or an initial public offering event for the company.

Other reports for Aktis Oncology, Inc.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.